In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Pharmaceuticals Incorporated

http://www.vrtx.com

Latest From Vertex Pharmaceuticals Incorporated

Albireo Dashes Into PFIC Market As FDA, EMA Approve Bylvay

The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

Rare Diseases Approvals

Vertex Inks New Cystic Fibrosis Deals In Europe

Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.

Europe Respiratory

Stock Watch: Why Have Biotech Acquisitions Paused?

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

M & A Stock Watch

US Supreme Court Limits Estoppel Rule In Blow To PhRMA

Ruling keeps the principle of assignor estoppel in place, but restricts its use to situations where an inventor’s claims in court directly contradict those in the patent.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics
UsernamePublicRestriction

Register

;